Pharma POOL
Dr. Zhi Hong
GSK Appoints Head, Infectious-Diseases Research Center Healthcare company
GlaxoSmithKline, Philadelphia, has appointed Zhi Hong, Ph.D., to lead a newly organized research unit dedicated to discovering therapies for infectious diseases. Dr. Hong heads the Infectious Diseases Center of Excellence for Drug Discovery (ID CEDD). He was previously executive VP and chief scientific officer of Ardea Biosciences. Donald R. Joseph Institute for OneWorld Health Names Chief Operating Officer The Institute for OneWorld Health, San Francisco, the first nonprofit pharmaceutical company in the United States, has named Donald R. Joseph, J.D., as chief operating officer. Mr. Joseph has served as interim senior VP, operations, for OneWorld Health since January. Previously, he was senior VP, corporate development, and general counsel at Renovis. Mr. Joseph holds a J.D. from the University of Texas Law School, with honors, and received his B.A. from the University of Oklahoma, with highest honors. Denise Quigley New Hire at Eisai Denise Quigley has joined pharmaceutical company Eisai, Woodcliff Lake, N.J., as product manager. Ms. Quigley oversees various marketing activities within the CNS franchise. Before joining Eisai, she was a product manager at PDL BioPharma. She holds a bachelor of arts in English from the University of Connecticut, an MBA in marketing from Sacred Heart University, and an MPA in health policy and administration from Rutgers University. Biotech POOL Iksung Cho Dr. Anthony J. Coyle Dr. Barbara White MedImmune Promotes in Key Scientific and Medical Roles MedImmune, Gaithersburg, Md., which is focused on the areas of infectious diseases, cancer, and inflammatory diseases, has added to its R&D and medical organizations. The promotions include Iksung Cho, VP, biostatistics; Anthony J. Coyle, Ph.D., VP, R&D, and head, inflammation and autoimmunity research; and Barbara White, M.D., VP, clinical development, inflammatory disease. Mr. Cho manages a team of statisticians conducting activities such as clinical-trial design and analysis for MedImmune’s R&D, clinical, regulatory, and manufacturing organizations. Previously, he was the primary statistician for the influenza vaccine program. He holds masters’ of science degrees in mathematics and statistics from Virginia Polytechnic Institute and State University. Dr. Coyle oversees MedImmune’s preclinical research in disease areas such as asthma, lupus, rheumatoid arthritis, and sepsis. He earned his bachelor of science and doctoral degrees in pharmacology from Kings College of the University of London. Before her promotion, Dr. White was head of the inflammatory disease group in clinical development. She received her medical degree from the University of Pennsylvania School of Medicine and completed her postdoctoral studies in basic cellular immunology at the National Institutes of Health. Dr. Christian Reich Genstruct Appoints VP, Scientific Research Biotechnology company Genstruct has appointed Christian Reich, M.D., Ph.D., as VP, scientific research. Dr. Reich leads Genstruct’s internal biology research teams as well as efforts in translational medicine and clinical research in partnership with its pharmaceutical partners. Before joining Genstruct, Cambridge, Mass., Dr. Reich worked for Millennium Pharmaceuticals. He received his bachelor’s degree in preclinical training from Humboldt University in Berlin and holds an M.D. and Ph.D. from the Medical University of Lubeck. Biopharmaceutical POOL Rob Bancroft Mike Bernstein Joe Santoro Dr. Herbert B. Slade Michael Steadman DFB Promotes and Appoints Senior Management DFB Branded Pharmaceuticals, part of DFB Pharmaceuticals, Fort Worth, Texas, has promoted Rob Bancroft to general manager of Healthpoint, part of DFB Branded Pharmaceuticals. DFB is a privately held corporation that provides technology-driven pharmaceutical products, outsourcing services, and licensing opportunities through its affiliate partners to the healthcare industry worldwide. Previously, Mr. Bancroft was senior VP, sales and marketing, Healthpoint Tissue Management. He has a bachelor of science degree in biology from Indiana University and an MBA in marketing and finance from the University of Southern California. Mike Bernstein has been appointed VP, regulatory affairs, for DFB Branded Pharmaceuticals, Joseph Santoro was promoted to VP, Sales and Healthcare Systems, and Herbert (Bert) B. Slade, M.D., has been appointed chief medical officer and senior VP, medical affairs. As VP, Mr. Bernstein focuses on DFB’s commercial branded businesses, Healthpoint and Coria Laboratories. Mr. Bernstein was previously VP, regulatory affairs, for the holding company. He received a bachelor of science degree from Pratt Institute and a master of public health degree from Tulane University. Mr. Santoro, an 18-year wound care industry veteran, was most recently VP of Healthpoint Tissue Management’s Healthcare Systems group. Mr. Santoro graduated from Indiana University in Bloomington with a B.S. degree in business administration. He served in several sales and marketing positions for the wound and skin care division of another healthcare company before joining Healthpoint in 1993. Dr. Slade’s focus is DFB’s clinical development capability and the development of products and therapies to complement existing wound care, surgical, and dermatological portfolios. Before joining DFB, Dr. Slade was director, worldwide medical and scientific affairs, at 3M Pharmaceuticals. He earned his undergraduate degree in biology from Hamilton College and his medical degree from State University of New York. Promoted to group president and chief operating officer, Michael Steadman leads DFB Branded Pharmaceuticals, a new segment of the company that encompasses four formerly affiliate divisions: Healthpoint, Tissue Management; Coria Laboratories; Healthpoint International; and Healthpoint Surgical. Mr. Steadman manages all operations of the enterprise. Previously, he was president of Healthpoint Tissue Management, and he continues to serve as chairman of the board of DFB Biotech of Curaçao N.V. and senior VP, DFB Pharmaceuticals. Laurence P. Birch Neopharm Names President and CEO Neopharm, Waukegan, Ill., a publicly traded biopharmaceutical company dedicated to the research, development, and commercialization of new and innovative cancer drugs for therapeutic applications, has appointed Laurence P. Birch president and CEO. Most recently, Mr. Birch served in a senior operating position at Ohio Medical Corp. He is a CPA, and he earned an MBA from Northwestern University’s Kellogg Graduate School of Management. Dr. Philip P. Breitfeld David S. McCullough BioCryst Expands Management Team BioCryst Pharmaceuticals, Birmingham, Ala., has expanded its management team with the appointment of Philip P. Breitfeld, M.D., as executive director, oncology development, and associate chief medical officer, and David S. McCullough as VP, strategic planning and commercialization. BioCryst uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling, to develop new therapeutic candidates. Before joining BioCryst, Dr. Breitfeld was medical director, oncology, at EMD Pharmaceuticals. He received his A.B. in chemistry from Princeton University and his M.D. from the University of Rochester, School of Medicine. Mr. McCullough most recently worked as director, global corporate development, in the Ethical Pharmaceuticals Division at Merck KGaA. He received his bachelor of science from Western Illinois University. Paul F. Duffy Amarin Appoints President, U.S. Commercial Operations Amarin has named Paul F. Duffy as president of U.S. commercial operations. Mr. Duffy’s goal is to build London-based Amarin’s U.S. commercial operation as the company advances its pipeline to bring a number of CNS therapeutics to market. He is located in the company’s New Jersey office. Mr. Duffy was previously CEO of Validus Pharmaceuticals. Michael V. Novinski Emisphere Names President and CEO Biopharmaceutical development company Emisphere Technologies, Tarrytown, N.Y., has appointed Michael V. Novinski president and CEO. Emisphere develops oral forms of injectable drugs. Previously, Mr. Novinski was president of Organon USA. He earned a bachelor’s degree in biology from Washington and Jefferson College. Specialty POOL Scott Shively David Whitehead Alpharma Announces New Leadership Alpharma, Bridgewater, N.J., a global specialty pharmaceutical company, has made two changes in its pharmaceutical sales and marketing organization. Scott Shively has been appointed as senior VP, sales and marketing. Mr. Shively’s most recent assignment was interim president and CEO of Altana Pharma. David Whitehead has joined Alpharma as VP, sales. Mr. Whitehead’s most recent assignment was VP, sales, for the neuroscience division of Bristol-Myers Squibb. Dr. Shawn L. Silvestri Akorn Names New Product Development VP Akorn, Buffalo Grove, Ill., has named Shawn L. Silvestri, Ph.D., as VP, new product development. Akorn manufactures and markets sterile specialty pharmaceuticals. Before joining Akorn, Dr. Silvestri served as director of the Abbott Diagnostics Division. He received a B.S. in pharmacy from Duquesne University and a Ph.D. in pharmaceutical sciences-pharmaceutics from the University of Connecticut. Emerging POOL Dr. Stephane Allard EpiCept Names Chief Medical Officer EpiCept, Tarrytown, N.Y., has appointed Stephane Allard, M.D., as chief medical officer. EpiCept is an emerging specialty pharmaceutical company that focuses on cancer treatments and pain management. Dr. Allard plays a pivotal role in the continued advancement of the company’s pain and cancer programs. Before his appointment at EpiCept, he was president of Allard and Associates. Dr. Allard received his M.D. from Rouen Medical College. Dr. Mark R. Bray Dr. Anthony M. Treston Senior R&D Management Promotions at EntreMed EntreMed, Rockville, Md., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, has promoted Mark R. Bray, Ph.D., to VP, research, and Anthony M. Treston, Ph.D., to VP, product development and manufacturing. Dr. Bray manages EntreMed’s Toronto R&D site, coordinates research activities between Rockville and Toronto, and manages the kinase inhibitor program, HDAC inhibitor program, and preclinical support for the MKC-1 program. Previously, he was senior director, preclinical sciences. Dr. Treston is responsible for EntreMed’s activities associated with drug product and process development, including formulation, drug delivery, technology transfer, and scale-up. He is responsible for manufacturing, including drug substance (API), drug product, and finish/fill for clinical trials, commercial production, and IND-enabling studies. Previously, he was senior director, medicinal and analytical chemistry. Dr. James E. Pennington Anthera Announces Appointment Anthera Pharmaceuticals, San Mateo, Calif., a privately held biopharmaceutical company developing anti-inflammatory drugs for chronic and acute diseases, has appointed James E. Pennington, M.D., as executive VP and chief medical officer. Dr. Pennington comes to Anthera from CoTherix, where he served as executive VP and chief medical officer. He earned his medical degree from the University of Oregon School of Medicine. Association POOL Cindy Cullen SAFE-BioPharma Association Names Chief Technology Officer Cindy Cullen, associate director of digital certificate services at Bristol-Myers Squibb, has been named chief technology officer for SAFE-BioPharma Association. SAFE-BioPharma, Fort Lee, N.J., is the nonprofit association that creates and manages the SAFE digital identity and digital signature standard for the pharmaceutical and healthcare industries. Ms. Cullen oversees and administers all aspects of technology for SAFE-BioPharma and is the chief systems architect for SAFE. She continues her Bristol-Myers Squibb responsibilities concurrently. Ms. Cullen holds an M.S. in computer science from City College of New York and a bachelor degree from St. Cloud State University. Agency POOL Denise Adams Jamie Coulson Brieanna Stout The Navicor Group Welcomes New Hires The Navicor Group, Columbus, Ohio, an inVentiv Health company and a full-service advertising agency, has named Denise Adams as creative project manager, Jamie Coulson as senior art director, and Brieanna Stout as editor. Ms. Adams is responsible for the agency’s overall deadlines, budgets, and quality of work. Before joining Navicor, she served as account manager at Baseman Printing. Ms. Coulson is responsible for developing creative strategies for advertising campaigns for assigned accounts. Most recently, she served as senior art director for Antibody Healthcare Communications. Ms. Stout is responsible for proofreading and editing assigned materials. Before her appointment at Navicor, she served as a freelance editor for another inVentiv Health company, Stonefly Communications Group. Dave Bowers GSW Worldwide Promotes Healthcare advertising agency GSW Worldwide, Columbus, Ohio, an inVentiv Health company, has promoted Dave Bowers to chief operating officer. Mr. Bowers, based in GSW Worldwide’s Columbus office, was previously executive VP, director of diversified agency services. He is responsible for identifying and implementing best practices, determining new and innovative ways to deliver services, and leading the development of over-arching agency operations. Karen Carr Chris Finch David Ostaszewski imc2 Expands Management Team Independent digital marketing agency imc2 has added three staff to its leadership team and healthcare practice in the Philadelphia office: Karen Carr, Chris Finch, and David Ostaszewski. As VP of strategy and leader of the company’s pharmaceutical and healthcare practice, Ms. Carr provides strategic planning, business innovation, and change management services. Before joining imc2, Ms. Carr was an associate partner and VP of strategy at Rosetta Marketing. Mr. Finch joins imc2 as director of client services. Previously, he was an account director for Refinery. Mr. Ostaszewski joins the agency as technology director. He is responsible for designing, planning, and implementation of business solutions, as well as providing technical support, guidance, and architecture to project team members. Before joining imc2, he was director of technology at Refinery. Dorothy Collins Dana Hays Tuyen Teasdale HealthEd Adds to Art and Account Management Teams HealthEd, Clark, N.J., a patient education marketing agency for pharmaceutical and healthcare marketers, has appointed Dorothy Collins as account supervisor. Ms. Collins is responsible for all aspects of account management. Before joining HealthEd, she was account management director at Tricor Interactive. Ms. Collins holds a bachelor’s degree in communications from Rowan University. HealthEd has named Dana Hays as art director. Ms. Hays is responsible for creating designs that support HealthEd’s patient education programs. Previously, she was a senior designer at Coyne Communications. Ms. Hays holds a bachelor of fine arts in visual communications/graphic design from Kean University. Tuyen Teasdale has joined HealthEd as senior art director. She manages the overall conceptual design and development for print and multimedia projects for HealthEd’s client portfolio. Before joining HealthEd, she owned and operated her own company, TNT Creative Studio. She holds a bachelor of fine arts degree in graphic design from the University of Kansas. Nick Colucci Publicis Healthcare Appoints President and CEO Nick Colucci has been appointed president and CEO of Publicis Healthcare Communications Group (PHCG), New York. Publicis Healthcare, a division of Publicis Group SA, is a communications group. As CEO, Mr. Colucci is responsible for all the companies of the Publicis Healthcare Communications Group, including Medical and Scientific Affairs, the Contract Sales Organization (Publicis Selling Solutions), and various digital businesses. He reports to John Farrell, President and CEO of Sp cialized Agencies & Marketing Services (SAMS), Publicis Groupe Worldwide. Former CEO Ed Rady has been named chairman and will remain in that position through the end of the year. A graduate of the University of Rochester, where he earned a B.S. in neuroscience, Mr. Colucci also has an MBA from Loyola College of Maryland. Eric Densmore Dan Lathitham AbelsonTaylor Bolsters Account Staff AbelsonTaylor, Chicago, an independent healthcare agency, has hired Eric Densmore as senior account supervisor and Dan Lathitham as account supervisor. Mr. Densmore, 32, oversees the agency’s account for a urology product for the treatment of overactive bladder. He returns to AbelsonTaylor from EURO RSCG Life Central. Mr. Densmore received his B.S. in marketing from the University of Illinois. Mr. Lathitham, 31, manages the agency’s account for Gilead’s Truvada for the treatment of HIV. He joins AbelsonTaylor from Ketchum. Mr. Lathitham holds a B.S. in advertising from the University of Illinois at Urbana-Champaign. Terrell Herring William O’DonnelL Blane Walter inVentiv Health Makes Executive Management Changes Terrell Herring has been promoted to the newly created position of chief operating officer of inVentiv Health Inc., Somerset, N.J. Mr. Herring fulfills this role in addition to his responsiblities as president and CEO of inVentiv Commercial and reports into Blane Walter, who is appointed to the newly created position of president of inVentiv Health. In this additional role, Mr. Herring leads the organization to more effectively deliver cross-selling and integrated solutions to clients, implement a single operational backbone to support inVentiv’s scale and growth, and assimilate additional acquisitions into the organization. Mr. Herring, who joined inVentiv in 1999, brings more than 20 years of experience in the pharmaceutical industry. William O’Donnell has been promoted to president and chief operating officer of inVentiv Communications, reporting to Mr. Walter. Mr. O’Donnell has served as CFO and chief administrative officer of inVentiv Communications since 2001, with responsibility for providing strategic financial and administrative management, acquisitions, partnerships and joint ventures, and overseeing accounting/finance, human resources, marketing communications, and technology departments. Before joining inVentiv Communications, Mr. O’Donnell spent 17 years with Bank One. In his new role, Mr. Walter’s focus is on overseeing the day-to-day operations of the company’s divisions and strategic integration across them to continue driving profitable growth, developing new client solutions, and enhancing a single integrated positioning to clients. Mr. Walter currently is president and CEO of inVentiv Communications and previously served as CEO and principal owner of inChord Communications, which inVentiv acquired in October 2005. Emily Poe Vox Medica Health-Care Public Relations Group Names New VP Vox Medica, Philadelphia, an independent healthcare communications company, has named Emily Poe as VP in the Public Relations Group. She is the team lead on a national outreach campaign promoting awareness of Alzheimer’s disease within Hispanic communities. Ms. Poe comes to Vox Medica from Cohn & Wolfe, where she served as VP. Service POOL Suzanne Burrell Rob Hoff Beth Kinsella Total Learning Concepts Promotes Total Learning Concepts, Boston, a Publicis Selling Solutions Group and Publicis Healthcare Communications Group company, has made several new hires and promotions. Suzanne Burrell has been promoted to VP, operations. Ms. Burrell is responsible for the daily business operations for the offices in Boston and Lawrenceville, N.J. Most recently, Ms. Burrell served as senior director, strategic initiatives and training. Rob Hoff has been promoted to senior director, creative services, and Beth Kinsella has been promoted to senior director, quality assurance. Consulting POOL John D’Antonio Todd Evans Michael Keech John Knapp PricewaterhouseCoopers Expands Pharmaceutical Industry Practice PricewaterhouseCoopers (PwC), New York, a provider of industry-focused services for public and private clients, has appointed John D’Antonio, Todd Evans, Michael Keech, and John Knapp as directors within its Global Pharmaceutical and Life Sciences Advisory Practice. Based in PwC’s Philadelphia office, Mr. D’Antonio advises pharmaceutical, biopharmaceutical, and medical-device clients on operations improvement, cost reduction, outsourcing, and functional strategy development in manufacturing and supply chain, finance, and other back-office functions. Mr. Evans works with clients on a wide range of channel strategy and supply chain management issues to help them achieve competitive advantage. Based in PwC’s Chicago office, his focus is new product launch planning and mature product channel realignment strategies. Mr. Keech is based in PwC’s Boston office. He advises clients on product development and commercialization strategy, R&D management, supply chain strategy, manufacturing, distribution, procurement, and customer service performance. Mr. Knapp is a healthcare attorney by background and has extensive operational and compliance experience. Based in PwC’s Philadelphia office, he advises clients in the areas of governance, risk, and compliance, as well as performance improvement. Shelli Field Paragon Names Chief Operating Officer Shelli Field has been named chief operating officer for Paragon Research and Consulting, West Chester, Pa., a privately held commercial market research and consulting company focused on the pharmaceutical, biotech, and healthcare industries. Ms. Field’s primary focus is the analytical competency of Paragon through advanced customer interfaces. She comes to Paragon from TVG Market Research where she was president. Glen Giovanetti Scott Sarazen New Leaders Appointed at Ernst & Young’s Global Biotechnology Center Ernst & Young has made two new leadership appointments at the company’s newly created Global Biotechnology Center in Boston. Glen Giovanetti has been named leader of the Global Biotechnology Center and Scott Sarazen has been appointed to global markets leader within the center. Mr. Giovanetti has extensive experience assisting biotechnology and medical-device clients with strategic transactions, including initial public offerings, public and private debt offerings, technology licensing and R&D contracts, and acquisitions. Mr. Sarazen brings more than 18 years of private and public sector biotechnology industry experience to the firm. His previous positions include senior VP for life sciences with MassDevelopment and director of global planning and development at Genzyme. The center is the hub of the company’s network of professionals dedicated to serving the global biotech market and connecting people and sharing information and experience on current and emerging industry issues. Venk Ramakrishnan Ziment Appoints Chief Methodologist Ziment Group, New York, a healthcare market-research consultancy, has appointed Venk Ramakrishnan to serve as chief methodologist. Ziment is the global healthcare research brand for The Kantar Group, the information and consultancy division of WPP. Mr. Ramakrishnan is responsible for bringing the most appropriate, creative multivariate techniques to bear against difficult strategic issues and for day-to-day product development at Ziment. Medical-Education POOL Dr. Gary C. Bird AlexAndria M. Kung PeerPoint Announces New Personnel Appointments PeerPoint Medical Education Institute, Evanston, Ill., an ACCME-accredited provider of continuing medical education to physicians and other healthcare professionals, has named two new medical education professionals. Gary C. Bird, Ph.D., is responsible for working with various medical faculties and writing program contents for PeerPoint. Dr. Bird has an MSC in pharmacology from the University of Southampton and a Ph.D. in neuroscience from the University of Leeds. AlexAndria M. Kung, MPH, is the senior liaison at PeerPoint, working with different medical faculties involved with CME. Ms. Kung has an MPH from Tulane University School of Public Health and Tropical Medicine, and she is working toward her Ph.D. in integrative medicine. Larry Mickelberg Digitas Health Promotes Digitas Health, Philadelphia, has promoted Larry Mickelberg to executive VP. Digitas Health is a next-generation marketing agency brand for healthcare. Mr. Mickelberg is part of the executive leadership team of Digitas Health, which unites Medical Broadcasting Company (MBC) with the healthcare practice of Digitas agency. He leads business development across the agency’s four offices as well as directs corporate and account strategy. Previously, Mr. Mickelberg served as senior VP, strategy and enablement at MBC. Technology POOL James P. Shaffer Clinical Data Hires for PGxHealth Division Global technology company Clinical Data, Newton, Mass., has hired James P. Shaffer as VP, sales and marketing, for the PGxHealth division, the provider of therapeutic diagnostics and its PGxPredict line of pharmacogenetic tests. Mr. Shaffer comes to Clinical Data from New River Pharmaceuticals, where he was VP, sales and marketing. He holds an MBA in marketing from Ohio State University. Send your personnel announcements to [email protected].
